48 results

• Eli Lilly-Funded Study Claims Side Effects of Olumiant Do Not Warrant Same Adverse Label Warnings as Xeljanz

  November 16, 2021

  Irvin Jackson

  A new study announced by Eli Lilly appears to suggest Olumiant, a rheumatoid arthritis drug, does not need the same label warnings for heart problems as Xeljanz, it's competitor.

• Xeljanz Heart Risks May Be Similar Across Other JAK Inhibitors Like Rinvoq, Oluminant: Study

  November 12, 2021

  Irvin Jackson

  A new study suggests the risk of heart problems linked to Xeljanz is similar across all other rheumatoid arthritis drugs belonging to the same class of medications.

• Xeljanz FDA Label Warning Update Adds Information About Risk of Cancer, Blood Clots and Heart Side Effects

  September 2, 2021

  Irvin Jackson

  The FDA is requiring new label warnings for Xeljanz and similar drugs, following a review which revealed links between increased risks of heart attacks, strokes, blood clots, and lymphomas, as well as an increased risk of lung cancer for current or former smokers.

• Experts, FDA Concerned Xeljanz Heart and Cancer Problems May Affect Similar Arthritis Drugs

  July 28, 2021

  Irvin Jackson

  Drugs in the same class as Xeljanz face increased scrutiny over concerns they may carry similar heart and cancer risks such as those suspected of plaguing the arthritis drug.

• Side Effects of Stelara May Trigger Severe Cardiovascular Events: Study

  October 26, 2020

  Irvin Jackson

  A new study warns that Stelara can significantly increase the risk of heart problems and strokes among patients already at a high risk of coronary events.

• Physical Therapy Better At Preventing Osteoarthritis Knee Pain Than Steroid Injections: Study

  April 17, 2020

  Martha Garcia

  A new study indicates patients with knee arthritis fare better with physical therapy than from receiving steroid injections for recovery and pain management.

• Xeljanz Side Effects at 10mg Dose Lead EMA To Place Restrictions on Use

  May 20, 2019

  Irvin Jackson

  European regulators have placed new restrictions on the use of Xeljanz while they continue to review potential pulmonary embolism risks.

• Lawsuit Over Xeljanz Generic Copy Filed by Pfizer

  April 3, 2019

  Irvin Jackson

  Pfizer is suing Ajanta Pharma over plans to release a generic version of Xeljanz years before its patent protection is scheduled to run out.

• Xeljanz Blood Clot Risk Seen With Higher Doses, EMA Warns

  March 25, 2019

  Austin Kirk

  Xeljanz side effects can cause pulmonary embolism at high doses, European drug regulators warn.

• Azasan, Imuran Side Effects May Increase Risk of Skin Cancer: Study

  September 12, 2018

  Irvin Jackson

  A new study links the drugs Azasan and Imuran to an increased risk of skin cancer.